Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + TNT in Locally Advanced Rectal Cancer
NCT04293419Phase 2Unknown
- Sponsor
- GEMCAD
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in rectal cancer, sponsored by GEMCAD. Status: unknown.
02
Drugs
durvalumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04293419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293419.